Vulvovaginal Candidiasis - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vulvovaginal Candidiasis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Vulvovaginal Candidiasis - Pipeline Review, H1 2015', provides an overview of the Vulvovaginal Candidiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vulvovaginal Candidiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vulvovaginal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vulvovaginal Candidiasis Overview 6
Therapeutics Development 7
Pipeline Products for Vulvovaginal Candidiasis - Overview 7
Pipeline Products for Vulvovaginal Candidiasis - Comparative Analysis 8
Vulvovaginal Candidiasis - Therapeutics under Development by Companies 9
Vulvovaginal Candidiasis - Pipeline Products Glance 10
Clinical Stage Products 10
Vulvovaginal Candidiasis - Products under Development by Companies 11
Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 12
Actavis plc 12
Grupo Ferrer Internacional, S.A. 13
NovaDigm Therapeutics, Inc. 14
Viamet Pharmaceuticals, Inc. 15
Vulvovaginal Candidiasis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
albaconazole - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
arasertaconazole - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NDV-3 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NDV-3A - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PEV-7 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
VT-1161 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Vulvovaginal Candidiasis - Recent Pipeline Updates 34
Vulvovaginal Candidiasis - Dormant Projects 38
Vulvovaginal Candidiasis - Discontinued Products 39
Vulvovaginal Candidiasis - Product Development Milestones 40
Featured News & Press Releases 40
Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 40
Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 40
Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 41
Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 42
Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 42
Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis 43
Jan 17, 2012: Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees 44
Oct 11, 2011: Pevion's Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity 45
Sep 01, 2011: Pevion Grants CSL Option Right To Therapeutic Candida Vaccine 45
Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Vulvovaginal Candidiasis, H1 2015 7
Number of Products under Development for Vulvovaginal Candidiasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Products under Development by Companies, H1 2015 11
Vulvovaginal Candidiasis - Pipeline by Actavis plc, H1 2015 12
Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 13
Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2015 14
Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2015 15
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Stage and Target, H1 2015 18
Number of Products by Stage and Mechanism of Action, H1 2015 20
Number of Products by Stage and Route of Administration, H1 2015 22
Number of Products by Stage and Molecule Type, H1 2015 24
Vulvovaginal Candidiasis Therapeutics - Recent Pipeline Updates, H1 2015 34
Vulvovaginal Candidiasis - Dormant Projects, H1 2015 38
Vulvovaginal Candidiasis - Discontinued Products, H1 2015 39